Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 2
1977 6
1978 2
1979 4
1980 3
1981 3
1982 1
1983 3
1984 3
1986 1
1987 3
1989 2
1992 1
1999 1
2004 1
2007 1
2013 1
2014 1
2015 1
2016 3
2018 2
2019 4
2020 6
2021 7
2022 5
2023 3
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. Eichhorst B, et al. N Engl J Med. 2023 May 11;388(19):1739-1754. doi: 10.1056/NEJMoa2213093. N Engl J Med. 2023. PMID: 37163621 Clinical Trial.
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.
de Jonge AV, Duetz C, Bruins WSC, Korst CLBM, Rentenaar R, Cosovic M, Eken M, Twickler I, Nijland M, van der Poel MWM, de Heer K, Klerk CPW, Strobbe L, Oosterveld M, Boersma R, Koene HR, Roemer MGM, van Werkhoven E, Chamuleau MED, Mutis T. de Jonge AV, et al. Among authors: de heer k. Blood Adv. 2024 Mar 12;8(5):1094-1104. doi: 10.1182/bloodadvances.2023011687. Blood Adv. 2024. PMID: 38191686 Free PMC article.
Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity.
Moreno-Arciniegas A, García A, Kelm M, D'Amore F, da Silva MG, Sánchez-González J, Sánchez PL, López-Fernández T, Córdoba R, Asteggiano R, Camus V, Smink J, Ferreira A, Kersten MJ, Bolaños N, Escalera N, Pacella E, Gómez-Talavera S, Quesada A, Rosselló X, Ibanez B; RESILIENCE Trial Investigators. Moreno-Arciniegas A, et al. Eur J Heart Fail. 2024 Oct;26(10):2213-2222. doi: 10.1002/ejhf.3395. Epub 2024 Aug 30. Eur J Heart Fail. 2024. PMID: 39212445
Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
Martens AWJ, Rietveld JM, de Boer R, Peters FS, Ngo A, van Mil LWHG, de Heer K, Spaargaren M, Verkleij CPM, van de Donk NWCJ, Adams HC 3rd, Eldering E, van Noesel CJM, Verona R, Kater AP. Martens AWJ, et al. Among authors: de heer k. Cancer Res Commun. 2022 May 9;2(5):330-341. doi: 10.1158/2767-9764.CRC-22-0083. eCollection 2022 May. Cancer Res Commun. 2022. PMID: 36875718 Free PMC article.
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.
Groen K, Stege CAM, Nasserinejad K, de Heer K, van Kampen RJW, Leys RBL, Thielen N, Westerman M, Wu KL, Ludwig I, Issa DE, Velders GA, Vekemans MC, Timmers GJ, de Boer F, Tick LW, Verbrugge A, Buitenhuis D, Cunha SM, van der Spek E, de Waal EGM, Sohne M, Sonneveld P, Nijhof IS, Klein SK, van de Donk NWCJ, Levin MD, Ypma PF, Zweegman S. Groen K, et al. Among authors: de heer k. EClinicalMedicine. 2023 Aug 29;63:102167. doi: 10.1016/j.eclinm.2023.102167. eCollection 2023 Sep. EClinicalMedicine. 2023. PMID: 37680948 Free PMC article.
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.
Groen K, Smits F, Nasserinejad K, Levin MD, Regelink JC, Timmers GJ, de Waal EGM, Westerman M, Velders GA, de Heer K, Leys RBL, van Kampen RJW, Stege CAM, Seefat MR, Nijhof IS, van der Spek E, Klein SK, van de Donk NWCJ, Ypma PF, Zweegman S. Groen K, et al. Among authors: de heer k. Hemasphere. 2024 Jul 4;8(7):e85. doi: 10.1002/hem3.85. eCollection 2024 Jul. Hemasphere. 2024. PMID: 38966208 Free PMC article. No abstract available.
Low-dose iron chelation as anti-oxidative therapy in patients with sickle cell disease: A single-centre pilot study.
Gaartman AE, Beuger BM, de Ligt LA, Veldthuis M, Matlung HL, Meijers JCM, Schalkwijk CG, de Heer K, Heijmans J, van Zwieten R, Biemond BJ, van Bruggen R, Nur E. Gaartman AE, et al. Among authors: de heer k. Br J Haematol. 2024 Dec 6. doi: 10.1111/bjh.19943. Online ahead of print. Br J Haematol. 2024. PMID: 39639778 No abstract available.
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP. Leeksma AC, et al. Among authors: de heer k. Leukemia. 2019 Feb;33(2):390-402. doi: 10.1038/s41375-018-0215-9. Epub 2018 Jul 23. Leukemia. 2019. PMID: 30038380 Free PMC article.
69 results